What question did this study set out to answer?

This research evaluates the long-term outcomes of cemiplimab monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high PD-L1 expression.

March 21, 2026Open Access

72P Cemiplimab monotherapy for first-line advanced NSCLC patients with PD-L1 expression ≥50%: 6-y outcomes of EMPOWER-Lung 1

Key Points

This research evaluates the long-term outcomes of cemiplimab monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high PD-L1 expression.
Analyzed outcomes of 30 NSCLC patients receiving cemiplimab monotherapy.
Recorded treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs).
Assessed efficacy based on progression-free survival (PFS) across different PD-L1 expression levels.
61.5% efficacy observed in advanced NSCLC patients with PD-L1 expression ≥50%.
40% of patients reported grade 3 treatment-related adverse events.
33.3% experienced immune-related adverse events, with 6.7% being grade 3.
13.3% of patients discontinued treatment due to adverse events.

Abstract

was 61.5%; PFS was not mature.Efficacy was observed across PD-L1 levels in both NSQ and SQ NSCLC (Table ).Across 30 pts with NSCLC (NSQ and SQ), 40.0% reported Gr 3 treatment-related AEs (TRAEs) and 33.3% reported immune-related (irAEs) that were Gr 3 in 6.7%.TRAEs led to treatment discontinuation in 13.3% pts.No TEAEs resulted in death.The safety profile was comparable between NSQ and SQ NSCLC.Conclusions: Pumitamig showed preliminary antitumor activity across PD-L1 levels and acceptable safety in pts with advanced NSCLC, including SQ cell carcinoma.Pumitamig + chemo in pts with NSCLC is being further investigated in ongoing global studies including ROSETTA Lung-02 (NCT06712316) and BNT327-07 (NCT06841055).Clinical trial identification: NCT05918445.

AI에게 질문

Bookmark

View Full Paper